ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,770.20
0.55%
US Tech 100
19,636.04
0.55%
Dow Jones
42,801.72
0.52%
Brent Oil
70.235
0.00%
Bitcoin
86,328.62
-0.49%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Oruka Therapeutics Inc (ORKA) Quote

Oruka Therapeutics Inc

Oruka Therapeutics Inc (ORKA)

NASDAQ
10.46
0.39
(3.87%)
Closed March 08 4:00PM
Delayed by 15 minutes
10.46
0.02
(0.19%)
After Hours: 7:50PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
10.46
Bid
8.59
Ask
14.00
Volume
261,784
9.58 Day's Range 10.70
9.44 52 Week Range 31.13
Market Cap
366.085M
Previous Close
10.07
Open
9.98
Last Trade
37
@
10.46
Last Trade Time
Financial Volume
$ 2,692,143
VWAP
10.2838
Average Volume (3m)
331,688
Shares Outstanding
34,998,550
Dividend Yield
-
PE Ratio
-68.46
Earnings Per Share (EPS)
-0.15
Revenue
-
Net Profit
-5.34M

About Oruka Therapeutics Inc

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome ... ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Show more

Sector
In Vitro,in Vivo Diagnostics
Industry
In Vitro,in Vivo Diagnostics
Website
www.orukatx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Oruka Therapeutics Inc is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker ORKA. The last closing price for Oruka Therapeutics was $10.07. Over the last year, Oruka Therapeutics shares have traded in a share price range of $ 9.44 to $ 31.13.

Oruka Therapeutics currently has 34,998,550 shares outstanding. The market capitalization of Oruka Therapeutics is $352.44 million. Oruka Therapeutics has a price to earnings ratio (PE ratio) of -68.46.

Ask ADVFN Intelligence (AI)

ORKA Latest News

More News

Form POS AM - Post-Effective amendments for registration statement
Edgar (US Regulatory)
March 06 2025
ORKA (3.87%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
March 06 2025
ORKA (3.87%)

Form 8-K - Current report
Edgar (US Regulatory)
February 05 2025
ORKA (3.87%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 24 2025
ORKA (3.87%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 24 2025
ORKA (3.87%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
January 24 2025
ORKA (3.87%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.777.946336429319.6910.899.4415701110.10363834CS
4-2.55-19.600307455813.0113.479.4426125610.80363391CS
12-10.65-50.450023685521.1123.579.4433168815.67765617CS
26-14.53-58.143257302924.9931.139.4422025218.64449827CS
52-18.54-63.93103448282931.139.4421394318.66617434CS
156-18.54-63.93103448282931.139.4421394318.66617434CS
260-18.54-63.93103448282931.139.4421394318.66617434CS

ORKA - Frequently Asked Questions (FAQ)

What is the current Oruka Therapeutics share price?
The current share price of Oruka Therapeutics is $ 10.46
How many Oruka Therapeutics shares are in issue?
Oruka Therapeutics has 34,998,550 shares in issue
What is the market cap of Oruka Therapeutics?
The market capitalisation of Oruka Therapeutics is USD 352.44M
What is the 1 year trading range for Oruka Therapeutics share price?
Oruka Therapeutics has traded in the range of $ 9.44 to $ 31.13 during the past year
What is the PE ratio of Oruka Therapeutics?
The price to earnings ratio of Oruka Therapeutics is -68.46
What is the reporting currency for Oruka Therapeutics?
Oruka Therapeutics reports financial results in USD
What is the latest annual profit for Oruka Therapeutics?
The latest annual profit of Oruka Therapeutics is USD -5.34M
What is the registered address of Oruka Therapeutics?
The registered address for Oruka Therapeutics is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Oruka Therapeutics website address?
The website address for Oruka Therapeutics is www.orukatx.com
Which industry sector does Oruka Therapeutics operate in?
Oruka Therapeutics operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ABLVAble View Global Inc
$ 1.73
(137.18%)
5.14M
SUNESUNation Energy Inc
$ 0.402999
(127.55%)
482.05M
BTOGBit Origin Ltd
$ 0.6117
(118.46%)
622.67M
DWTXDogwood Therapeutics Inc
$ 6.63
(49.66%)
25.92M
KZIAKazia Therapeutics Ltd
$ 1.1899
(40.80%)
4.5M
ALBTAvalon GloboCare Corporation
$ 6.96
(-36.15%)
577.55k
SCNXScienture Holdings Inc
$ 1.55
(-35.68%)
1.59M
ACXPAcurx Pharmaceuticals Inc
$ 0.4572
(-29.88%)
1.18M
RETOReTo Eco Solutions Inc
$ 5.42
(-27.73%)
108.27k
OCTOEightco Holdings Inc
$ 1.08
(-27.03%)
336.99k
BTOGBit Origin Ltd
$ 0.6117
(118.46%)
618.03M
SUNESUNation Energy Inc
$ 0.402999
(127.55%)
476.73M
NVDANVIDIA Corporation
$ 112.69
(1.92%)
333.91M
ICONIcon Energy Corporation
$ 0.169898
(17.17%)
140.23M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 10.675
(-0.70%)
140.05M

Discussion

View Full Feed
JoeForkeyBolo JoeForkeyBolo 3 minutes ago
I updated the MONI Decision Wheel to include options for Reverse Splits. I thought MONI management might need that option in order to upgrade to OTCQB since they are unable to maintain closing share price above $0.01 for 30 days on their own.

https://wheelofnames.com/dm7-db6 Moon Eq
MONI
Dingbatt Dingbatt 9 minutes ago
https://www.yahoo.com/entertainment/gene-hackman-died-of-heart-disease-betsy-arakawa-died-of-hantavirus-medical-examiner-214220628.html
Ok thats the report but there are a number of issues that defy common sense
The dog was dead in a cage and his wife was dead on the floor in the bat
eagle8 eagle8 9 minutes ago
kristen shaughnessy
@kshaughnessy2
How much money would Robinhood have lost if it didn't restrict trading in $GME and $AMC?

Instead it pays a $29.5 Million Fine-and admits no wrongdoing- to settle several investigations into how it does business

"FINRA s
AMC GME
gregcod gregcod 10 minutes ago
IBATS plant is probably already mised out by now, but a plant w IBAT can be built in less than a year! already tested and proven more than any other DLE, and its Modular.IBAT is number one IMO, and others will take years to make.
IBATF
KILLAZILLA KILLAZILLA 18 minutes ago
TRUTH BS FICTION....

you LOSE!!!
XERI
JamesLH JamesLH 19 minutes ago
Proof is the fact that not a single person has received any subpoenas, and you refuse to post the actual subject subpoenas and fake police reports, we all know if you actually had it you would brag about it 8x a day!! Hahahaa

Nick Campanella, I know you read these posts and are crying
SNPW
Bob Mullet Bob Mullet 23 minutes ago
Don't believe u boiler room bob. 
KBLB
JoeForkeyBolo JoeForkeyBolo 25 minutes ago
Very revealing on Nasdaq, yessiree!! I wonder what next week on Nasdaq will reveal.

https://investorshub.advfn.com/uimage/uploads/2025/3/8/ndlimScreen_Shot_2025-03-08_at_3.02.34_AM.png
IBIO
eagle8 eagle8 29 minutes ago
d_stock
@d_stock07734
Immunotherapy for Glioblastoma: Overcoming Resistance with Linda M. Liau, MD, PhD, MBA
https://youtu.be/fMxjVRRSdXE?t=2673

Q: This was amazing and uh thank you for not only putting it all together but presented to us with the great enthusiasm
NWBO
satter satter 29 minutes ago
Take a guess how much financial aide the US sends Canada EVERY year year

That question was likely asked seeking the false Trump lie that you and the rest of the magas spew. I'll post the correct response below.

The U.S. has not spent more than $35.1 million in a single
WojD40 WojD40 35 minutes ago
I find this credible. It kinda makes sense to cull those investors whose frustration has turned into hostility.
NWBO
eagle8 eagle8 37 minutes ago
Andrew Caravello, DO reposted
Wiz888999
@ODB123
🔥 BREAKING: META MATERIALS BANKRUPTCY CASE TARGETS CITADEL SECURITIES! 🔥

A Nevada Bankruptcy Court just granted an order forcing Citadel Securities to appear for examination regarding Meta Materials'
GME
Seminole Red Seminole Red 39 minutes ago
WASHINGTON (Reuters) - President Donald Trump's administration on Friday fired the head of the U.S. Justice Department office that handles presidential pardon requests, the official said in a social media post.

Liz Oyer served as pardon attorney since 2022, a career Justice Department
4u2nv2 4u2nv2 43 minutes ago
I have not even started here. "Reg D offerings, particularly under Rule 506(c), are limited strictly to accredited investors, which can streamline the fundraising process since these investors are typically more experienced and capable of making larger investments; however, it also limits the pool o
IFUS
WojD40 WojD40 43 minutes ago
Dilution ends with approval. I'm certain of this. The big question is The Uplist. If there is no guidance about when the company plans to return to the NASDAQ then chances are we're waiting until FDA approval to push the company with Institutional Investors and past the lunatic retail fringe.
NWBO
Seminole Red Seminole Red 46 minutes ago
Missouri AG Says New Discovery Could Make Biden’s Actions as President Null And Void

https://tfppwire.com/missouri-ag-says-new-discovery-could-make-bidens-actions-as-president-null-and-void/?fbclid=IwY2xjawI44bJleHRuA2FlbQIxMAABHXpYbO3Ze5soE0ee0eqi-ZOXkFI8ysbzBKqerzrvipeEsKQ2jKVNMhXAf
chereb19 chereb19 47 minutes ago
Phase 1’s official checks are 30 and 90 day —but patients are still monitored between, common sense you’d grasp if you weren’t clueless.
RDGL
powerbattles powerbattles 49 minutes ago
For the Three Months Ended November 30, 2024, total revenues were 112,226,717 which is very good. Compared to last year's revenue of 61,842,253.
UNQL
ron_66271 ron_66271 50 minutes ago
Pick, You Are Not Very Good At Math.

Or Document history. Just like Lodas big ❌.

The $14 Billion Dollars for WMB Notes are JPM’s responsibility.
JPM bought the WMB Bank.
The $14 claim goes away when JPM pays for “WMB and its assets”. The WMB Notes a
JPM WMB
Cosa Cosa 50 minutes ago
From their website

What is a washout also? How long did patients stop taking previous binder?

https://ir.unicycive.com/news/detail/73/unicycive-therapeutics-achieves-study-objective-in

While the study was not designed to evaluate efficacy, the trial
UNCY
eagle8 eagle8 51 minutes ago
https://x.com/peter_brit/status/1898288449410486608/photo/1
NWBO
4u2nv2 4u2nv2 52 minutes ago
Reg D. Sandy J Arabie took the Reg D offering about 5 months ago. What does that involve? Ean got 10 million for driving the fork lift read that close to the bottom. Businesses decide to raise capital, they often consider Regulation A (Reg A) and Regulation D (Reg D) offerings. Each regulation offe
IFUS
powerbattles powerbattles 57 minutes ago
Yes, the 10-Q was out on 03-07-2025. I'm not sure why OTC status still shows a grace period. Maybe they will update by next week.
UNQL

Your Recent History

NASDAQ
ORKA
Oruka Therapeutics
NASDAQ
LPSN
LivePerson
BIT
S29629
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads